146 related articles for article (PubMed ID: 36129433)
1. Factors associated with pathologic complete response following neoadjuvant chemoradiation and esophagectomy for carcinoma of esophagus and gastroesophageal junction.
Nusrath S; Thammineedi SR; Raju KVVN; Patnaik SC; Saksena AR; Karthik J; Basude M; Kumar J P; Shukla S; Rao VB; Kumar C K; Gujjuru S; Tewani R; Rushdie T; Sudhir R; Smith LM; Are C
J Surg Oncol; 2023 Jan; 127(1):48-55. PubMed ID: 36129433
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemoradiation for locally advanced resectable carcinoma of the esophagus: A single-center experience from India with a brief review of the literature.
Krishnamurthy A; Mohanraj N; Radhakrishnan V; John A; Selvaluxmy G
Indian J Cancer; 2017; 54(4):646-651. PubMed ID: 30082551
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of neoadjuvant immunotherapy in resectable esophageal or gastroesophageal junction carcinoma: A pooled analysis of prospective clinical trials.
Zhu J; Leng X; Gao B; Wang B; Zhang H; Wu L; Ma J; Tan Y; Peng L; Han Y; Wang Q
Front Immunol; 2022; 13():1041233. PubMed ID: 36591306
[TBL] [Abstract][Full Text] [Related]
4. Induction Chemotherapy Plus Neoadjuvant Chemoradiation for Esophageal and Gastroesophageal Junction Adenocarcinoma.
Ho F; Torphy RJ; Friedman C; Leong S; Kim S; Wani S; Schefter T; Scott CD; Mitchell JD; Weyant MJ; Meguid RA; Gleisner AL; Goodman KA; McCarter MD
Ann Surg Oncol; 2021 Nov; 28(12):7208-7218. PubMed ID: 33884489
[TBL] [Abstract][Full Text] [Related]
5. Short-term outcome of Ivor Lewis esophagectomy following neoadjuvant chemoradiation versus perioperative chemotherapy in patients with locally advanced adenocarcinoma of the esophagus and gastroesophageal junction: a propensity score-matched analysis.
Plum PS; Damanakis A; Buschmann L; Ernst A; Datta RR; Schiffmann LM; Zander T; Fuchs H; Chon SH; Alakus H; Schröder W; Hölscher AH; Bruns CJ; Bludau M
J Cancer Res Clin Oncol; 2022 May; 148(5):1223-1234. PubMed ID: 34223965
[TBL] [Abstract][Full Text] [Related]
6. Perioperative chemotherapy vs. neoadjuvant chemoradiation in gastroesophageal junction adenocarcinoma : A population-based evaluation of the Munich Cancer Registry.
Münch S; Habermehl D; Agha A; Belka C; Combs SE; Eckel R; Friess H; Gerbes A; Nüssler NC; Schepp W; Schmid RM; Schmitt W; Schubert-Fritschle G; Weber B; Werner J; Engel J
Strahlenther Onkol; 2018 Feb; 194(2):125-135. PubMed ID: 29071366
[TBL] [Abstract][Full Text] [Related]
7. Neoadjuvant Chemotherapy versus Chemoradiation Prior to Esophagectomy: Impact on Rate of Complete Pathologic Response and Survival in Esophageal Cancer Patients.
Samson P; Robinson C; Bradley J; Lockhart AC; Puri V; Broderick S; Kreisel D; Krupnick AS; Patterson GA; Meyers B; Crabtree T
J Thorac Oncol; 2016 Dec; 11(12):2227-2237. PubMed ID: 27544058
[TBL] [Abstract][Full Text] [Related]
8. Perioperative chemotherapy versus neoadjuvant chemoradiotherapy for esophageal or GEJ adenocarcinoma: A propensity score-matched analysis comparing toxicity, pathologic outcome, and survival.
Goense L; van der Sluis PC; van Rossum PSN; van der Horst S; Meijer GJ; Haj Mohammad N; van Vulpen M; Mook S; Ruurda JP; van Hillegersberg R
J Surg Oncol; 2017 Jun; 115(7):812-820. PubMed ID: 28267212
[TBL] [Abstract][Full Text] [Related]
9. Accuracy of detecting residual disease after neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma (preSINO trial): a prospective multicenter diagnostic cohort study.
Zhang X; Eyck BM; Yang Y; Liu J; Chao YK; Hou MM; Hung TM; Pang Q; Yu ZT; Jiang H; Law S; Wong I; Lam KO; van der Wilk BJ; van der Gaast A; Spaander MCW; Valkema R; Lagarde SM; Wijnhoven BPL; van Lanschot JJB; Li Z
BMC Cancer; 2020 Mar; 20(1):194. PubMed ID: 32143580
[TBL] [Abstract][Full Text] [Related]
10. Influence of neoadjuvant therapy on outcomes in patients with resectable carcinoma of esophagus and gastro-esophageal junction from a tertiary cancer care center in India.
Rao T S; Raju KVVN; Patnaik SC; Reddy P; Saksena AR; Rajappa S; Mallavarapu KM; Santa A; Gudipudi D; Boleneni N; Usofi Z; Gujjuru S; Smith L; Are C; Nusrath S
J Surg Oncol; 2021 Jun; 123(7):1547-1557. PubMed ID: 33650697
[TBL] [Abstract][Full Text] [Related]
11. No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base.
Al-Sukhni E; Gabriel E; Attwood K; Kukar M; Nurkin SJ; Hochwald SN
J Am Coll Surg; 2016 Dec; 223(6):784-792.e1. PubMed ID: 27641320
[TBL] [Abstract][Full Text] [Related]
12. Low-Dose Radiation Yields Lower Rates of Pathologic Response in Esophageal Cancer Patients.
Mantziari S; Farinha HT; Messier M; Winiker M; Allemann P; Ozsahin EM; Demartines N; Piessen G; Schäfer M
Ann Surg Oncol; 2024 Apr; 31(4):2499-2508. PubMed ID: 38198002
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Clinical Efficacy of Neoadjuvant Chemoradiation Therapy Between Lower and Higher Radiation Doses for Carcinoma of the Esophagus and Gastroesophageal Junction: A Systematic Review.
Li Y; Liu H; Sun C; Yin X; Tong J; Zhang X; Wang X; Yuan X; Zhang Z; Lu G; Gu Y; Li Y; Huang T; Qiao Z; Chen Y
Int J Radiat Oncol Biol Phys; 2021 Oct; 111(2):405-416. PubMed ID: 33964352
[TBL] [Abstract][Full Text] [Related]
14. Worldwide trends in surgical techniques in the treatment of esophageal and gastroesophageal junction cancer.
Haverkamp L; Seesing MF; Ruurda JP; Boone J; V Hillegersberg R
Dis Esophagus; 2017 Jan; 30(1):1-7. PubMed ID: 27001442
[TBL] [Abstract][Full Text] [Related]
15. Neoadjuvant Therapy for Locally Advanced Esophageal Cancer Should Be Targeted to Tumor Histology.
Stiles BM; Kamel MK; Harrison SW; Rahouma M; Lee B; Nasar A; Port JL; Altorki NK
Ann Thorac Surg; 2019 Jan; 107(1):187-193. PubMed ID: 30278165
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Impact of Postoperative Lymph Node Metastases After Neoadjuvant Chemoradiotherapy for Locally Advanced Squamous Cell Carcinoma of Esophagus: From the Results of NEOCRTEC5010, a Randomized Multicenter Study.
Leng X; He W; Yang H; Chen Y; Zhu C; Fang W; Yu Z; Mao W; Xiang J; Chen Z; Yang H; Wang J; Pang Q; Zheng X; Liu H; Yang H; Li T; Zhang X; Li Q; Wang G; Mao T; Guo X; Lin T; Liu M; Fu J; Han Y
Ann Surg; 2021 Dec; 274(6):e1022-e1029. PubMed ID: 31855875
[TBL] [Abstract][Full Text] [Related]
17. Timing of esophagectomy after neoadjuvant chemoradiation treatment in squamous cell carcinoma.
Franko J; McAvoy S
Surgery; 2018 Sep; 164(3):455-459. PubMed ID: 29903507
[TBL] [Abstract][Full Text] [Related]
18. Impact of Extracapsular Lymph Node Involvement After Neoadjuvant Chemoradiation Therapy Followed by Surgery in Carcinoma of the Esophagus: A Multicenter Study.
Depypere LP; Moons J; Mariette C; D'Journo XB; Thomas PA; Hölscher AH; Bollschweiler E; van Berge-Henegouwen MI; Van Lanschot JJB; Lerut TEMR; Nafteux PR
Ann Surg; 2018 Dec; 268(6):1000-1007. PubMed ID: 28742714
[TBL] [Abstract][Full Text] [Related]
19. Nodal metastasis from locally advanced esophageal cancer: how neoadjuvant therapy modifies their frequency and distribution.
Castoro C; Scarpa M; Cagol M; Ruol A; Cavallin F; Alfieri R; Zanchettin G; Rugge M; Ancona E
Ann Surg Oncol; 2011 Dec; 18(13):3743-54. PubMed ID: 21556952
[TBL] [Abstract][Full Text] [Related]
20. Pathologic nodal status predicts disease-free survival after neoadjuvant chemoradiation for gastroesophageal junction carcinoma.
Gaca JG; Petersen RP; Peterson BL; Harpole DH; D'Amico TA; Pappas TN; Seigler HF; Wolfe WG; Tyler DS
Ann Surg Oncol; 2006 Mar; 13(3):340-6. PubMed ID: 16485154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
